PKD1 and PKD2: Their Function and Role in Kidney Disease

PKD1 and PKD2 are two genes that encode large proteins called polycystin-1 and polycystin-2, which work together as a molecular complex on the surface of kidney cells. When either gene carries a harmful mutation, the result is autosomal dominant polycystic kidney disease (ADPKD), the most common inherited kidney disorder. Roughly 85 percent of ADPKD cases trace to mutations in PKD1, with most of the remainder linked to PKD2, and the gene involved substantially shapes how quickly the disease progresses and when kidney failure arrives.

What PKD1 and PKD2 Actually Make

The PKD1 gene sits on chromosome 16 and encodes polycystin-1 (PC1), a very large membrane protein with a long extracellular portion that acts like an antenna or receptor. The PKD2 gene, on chromosome 4, encodes polycystin-2 (PC2), a smaller protein that functions as an ion channel. PC2 belongs to the TRP (transient receptor potential) superfamily of channels and lets cations, particularly sodium, potassium, and some calcium, flow across cell membranes.¹ Think of PC1 as the sensor and PC2 as the signal relay: PC1 detects something in the surrounding environment and modulates PC2’s channel activity in response.

These two proteins physically bind to each other through their intracellular tails. Structural studies using cryo-electron microscopy have shown that the human PKD1-PKD2 complex assembles in a ratio of one PC1 molecule to three PC2 molecules.² This 1:3 architecture matters because it tells us that PC2 is not just a silent partner; it forms the core of the channel pore, with a single PC1 molecule docked alongside. The complex sits in multiple cellular locations, but its most studied home is the primary cilium of kidney epithelial cells.

The Primary Cilium Connection

Nearly every kidney tubule cell sprouts a single hair-like projection called a primary cilium, which protrudes into the fluid flowing through the tubule. Both PC1 and PC2 localize to this cilium, where they are thought to help the cell sense its environment, including the flow of urine.³ For years, the working model was that fluid flow bends the cilium, activating a PC1-PC2 complex that lets calcium rush in and triggers downstream signals telling the cell to behave normally: stop dividing, maintain proper orientation, keep fluid transport in check.

That picture has become more complicated. Studies of collecting-duct cells have shown that PC2 can form a functional ion channel in the cilium even without PC1 present, which challenges the older idea that the two always work as an inseparable unit.⁴ The ciliary PC2 channel preferentially conducts potassium and sodium rather than calcium, and calcium at higher concentrations actually blocks the inward sodium current. Internal calcium does enhance the channel’s open probability, setting up a feedback loop where small calcium signals amplify PC2 activity. So while the calcium-signaling story is real, it is less of a simple on-off switch than researchers originally imagined.

PC2 also operates in locations beyond the cilium. It functions as a calcium-release channel in the endoplasmic reticulum, the cell’s internal calcium warehouse, and as a cation channel at the cell surface.¹ This means losing PC2 function disrupts calcium handling in multiple compartments at once, not just the cilium.

How Cysts Form When Polycystins Fail

ADPKD is inherited in a dominant fashion: you only need one bad copy of PKD1 or PKD2 from one parent to be at risk. But here is the puzzle. If every cell in the body already has that one bad copy from birth, why do cysts appear only in scattered spots rather than everywhere at once? The answer lies in what researchers call the two-hit model. A cyst begins forming only when the remaining good copy of the gene in a particular cell is also knocked out by a random, spontaneous mutation that occurs during a person’s lifetime.⁵

Direct evidence supports this. When researchers examined 30 individual kidney cysts from a patient with PKD2, they found that over a third of those cysts carried a second somatic mutation that had wiped out the remaining normal copy of the gene.⁵ A separate study of PKD2 cysts confirmed that these second hits land specifically on the copy inherited from the unaffected parent, reinforcing the idea that cystogenesis requires essentially zeroing out polycystin function in that cell.⁶

More recent work frames the threshold slightly differently. Rather than needing an absolute knockout, studies suggest that polycystin complex function just needs to drop below some critical level to trigger cyst formation.⁷ This “dosage” concept helps explain why some patients with milder mutations have slower disease: their polycystin levels are reduced but hover closer to the threshold rather than plummeting below it.

What Goes Wrong Inside Cystic Cells

Once polycystin function collapses in a cell, several signaling pathways go haywire simultaneously. Two of the most important involve a molecule called cAMP and a growth-regulating pathway called mTOR.

In healthy kidney cells, cAMP (cyclic adenosine monophosphate) plays a normal housekeeping role. In cells that have lost polycystin function, cAMP becomes an engine of cyst growth. It does this in two ways at once: it pushes the cyst-lining cells to multiply faster, and it drives those cells to pump chloride ions, and consequently fluid, into the cyst lumen, inflating the cyst like a water balloon.⁸ That fluid secretion depends on a chloride channel called CFTR, the same channel that is defective in cystic fibrosis.⁹ The involvement of CFTR in cyst fluid secretion was shown clearly when antisense molecules that reduced CFTR protein in polycystic kidney cells led to roughly a 73 percent drop in stimulated fluid secretion.⁹

The mTOR pathway, which normally helps cells decide whether to grow and divide, is also inappropriately switched on in ADPKD cyst-lining cells. PC1’s intracellular tail interacts with a protein called tuberin that normally keeps mTOR in check, and when PC1 is lost, that brake is released.¹⁰ The result is unchecked cell proliferation. Additional signals, including the inflammatory molecule MIF, feed into this mTOR activation in polycystin-deficient cells, creating multiple reinforcing loops that keep the growth signal blaring.¹¹

Metabolic Rewiring in Cystic Tissue

Beyond abnormal signaling, cystic kidney cells also rewire their metabolism in ways that resemble cancer cells. Healthy cells rely heavily on mitochondria to burn fuel efficiently, but cells that have lost polycystin function shift toward aerobic glycolysis, sometimes called the Warburg effect, where glucose is fermented even when oxygen is plentiful.¹² Alongside this shift, cystic cells show impaired fat burning, altered amino acid use, faulty autophagy (the cell’s internal recycling system), and dysfunctional mitochondria.¹³

This metabolic angle has opened up potential treatment ideas. If cystic cells depend on glycolysis and glutamine more than normal cells do, starving them of those fuels could slow cyst growth without harming healthy tissue. Animal studies have explored caloric restriction and specific metabolic inhibitors with some encouraging results, though none has yet reached routine clinical use.

PKD1 Versus PKD2 in Clinical Severity

If the same two-hit mechanism drives cyst formation regardless of which gene is affected, why does the gene involved matter so much for outcomes? The clinical difference is stark. In a large comparison study, the median age at kidney failure or death was about 53 years for people with PKD1 mutations but around 69 years for those with PKD2 mutations.¹⁴ That is roughly a 20-year gap. People with PKD2 were also less likely to develop high blood pressure, blood in the urine, and urinary tract infections compared to their PKD1 counterparts.¹⁴

Part of the explanation is probably statistical: the PKD1 gene is much larger than PKD2, which means there are more places along the gene where a random somatic “second hit” can land. More opportunities for second hits means more cysts developing earlier. There is also the question of mutation type. Not all PKD1 mutations are equal. Truncating mutations, which chop the protein short and usually destroy function, tend to produce more severe disease. Certain nontruncating mutations, which change the protein without chopping it, can produce a milder course that looks more like PKD2 disease on measures of kidney function and kidney volume.¹⁵

Even within the same family carrying the exact same PKD1 mutation, individuals can have very different disease courses. Research has shown that modifier genes in a person’s broader genetic background play a significant role in this variability, with evidence pointing to one or a few modifier genes that strongly influence the pace of disease progression.¹⁶ This means that knowing someone carries a PKD1 mutation tells you they likely face more aggressive disease than a PKD2 patient, but it cannot tell you exactly when they will reach kidney failure.

Beyond the Kidneys

Polycystins are not only found in kidney cells. They are expressed in the liver, pancreas, blood vessels, and other tissues, which is why ADPKD has consequences beyond the kidneys. Liver cysts are extremely common and can become large enough to cause discomfort, though they rarely impair liver function. More concerning is the link to brain aneurysms. Patients with ADPKD face an elevated risk of developing saccular intracranial aneurysms compared to the general population, and rupture of such an aneurysm can cause devastating bleeding in the brain.¹⁷ Current guidelines recommend screening for brain aneurysms in ADPKD patients who have a family history of aneurysm rupture or who work in high-risk occupations where sudden incapacitation could be dangerous. The link to cardiac complications has also been explored, with PKD1 patients showing a higher burden than PKD2 patients in terms of hospitalizations for heart-related problems.¹⁸

Tracking Progression With Imaging

Because kidneys in ADPKD grow steadily as cysts expand, total kidney volume measured from imaging scans has become a key tool for predicting how fast someone’s disease will worsen. The Mayo Imaging Classification system assigns patients to classes from 1A through 1E based on their height-adjusted kidney volume and age. Someone in class 1A might lose kidney function at roughly 1.5 mL/min per year, while someone in class 1E might lose it at more than 4.5 mL/min per year.¹⁹ Validation studies have confirmed that the classification system predicts kidney outcomes reasonably well, though it tends to somewhat overestimate the rate of decline in the most severe class.²⁰

This classification feeds directly into treatment decisions. Many clinicians use it to decide whether to start a patient on tolvaptan, the main approved drug for slowing ADPKD progression, since the drug’s side effects mean it is most worthwhile for people predicted to progress rapidly. An expanded version of the classification now also accounts for atypical kidney shapes, such as kidneys that are asymmetric or have features not well captured by the original scoring system.²¹

Tolvaptan and the cAMP Connection

The discovery that cAMP is a major driver of cyst growth pointed directly at a treatment target. Vasopressin, a hormone that helps the kidneys conserve water, works through a receptor (the V2 receptor) that raises cAMP levels in collecting-duct cells. Blocking that receptor should lower cAMP and slow cyst expansion, and that is exactly what tolvaptan does. Clinical trials showed that tolvaptan slows the increase in kidney volume, delays the decline in kidney function, and reduces kidney pain in patients with relatively preserved kidney function.²²

The trade-off is significant. Because the drug blocks the kidneys’ ability to concentrate urine, patients produce large volumes of very dilute urine, sometimes six liters or more per day. They need to drink constantly and get up multiple times at night. Liver toxicity is also a concern, requiring regular blood testing. These drawbacks mean tolvaptan is typically reserved for patients whose imaging and genetic profiles suggest they are at high risk of rapid progression, not prescribed universally to everyone with ADPKD.

A MicroRNA Angle That Could Change Treatment

One of the more promising research directions involves tiny regulatory molecules called microRNAs, particularly one called miR-17. MicroRNAs do not code for proteins themselves; instead, they latch onto messenger RNA molecules and silence them, reducing the production of specific proteins. In ADPKD, miR-17 targets the messenger RNAs of both PKD1 and PKD2, essentially turning down whatever polycystin production the remaining functional gene copy is trying to maintain.²³

Researchers have shown that editing out the miR-17 binding site in the PKD1 or PKD2 gene’s regulatory region stabilizes the messenger RNA, raises polycystin protein levels, and slows cyst growth in mouse models. Remarkably, boosting PKD2 expression through this approach slowed cyst growth even in models where PKD1 was the mutated gene, hinting that the two polycystins are somewhat interchangeable in terms of compensating for each other at the functional level.²³ In a more recent study, even a tiny six-nucleotide substitution that disrupted the miR-17 motif was enough to roughly triple the stability of PKD1 messenger RNA in kidney cells.²⁴

This is exciting because it could lead to treatments that work regardless of the specific mutation a patient carries. Instead of fixing the broken gene directly, the strategy props up whatever functional polycystin production remains. Antisense oligonucleotides targeting miR-17 have already entered early-stage clinical trials, and gene-editing approaches using CRISPR to knock out the miR-17 binding site are being explored in preclinical models.²⁵

Kidney Organoids as a Testing Ground

One bottleneck in ADPKD research has always been the difficulty of studying human cyst formation in real time. Mouse models are useful but do not perfectly replicate human disease. A newer approach uses kidney organoids, miniature kidney-like structures grown in the lab from human stem cells. By using gene editing to knock out PKD1 or PKD2 in stem cells and then coaxing those cells into organoid form, researchers can watch cysts emerge and expand over days in a dish.²⁶

These organoid systems reproduce a key clinical observation: PKD1-knockout organoids form cysts more robustly than PKD2-knockout organoids, mirroring the more aggressive disease seen in PKD1 patients.²⁷ Because these platforms are scalable, they can be used for high-throughput drug screening, testing thousands of compounds for their ability to shrink cysts or slow their growth. Patient-derived organoid cultures have already been used to validate the miR-17 binding-site editing strategy, showing smaller cysts and reduced cell proliferation in the edited lines.²³

Polycystins Outside Mammals

Polycystins are not a human invention. Versions of these proteins exist in organisms spanning the animal kingdom, including the tiny roundworm C. elegans. In worms, polycystins localize to cilia on specialized sensory neurons used in mating behavior. The discovery that polycystins sit on cilia in C. elegans actually helped steer the field toward investigating cilia in mammalian kidney cells, a connection that proved central to understanding ADPKD. Worm studies have also opened up research into how cells release tiny membrane-bound packages called extracellular vesicles from their cilia, a process that may have broader biological significance beyond kidney disease.

The conservation of polycystins across such distant species suggests these proteins are performing something fundamental in how cells interact with their external environment. Understanding that ancient function continues to generate insights that might eventually translate into treatments for the human disease.